Techno Medica Management
Management criteria checks 2/4
Techno Medica's CEO is Masatomo Saneyoshi, appointed in Jun 2014, has a tenure of 10.5 years. directly owns 2.99% of the company’s shares, worth ¥380.05M. The average tenure of the management team and the board of directors is 8.5 years and 6.5 years respectively.
Key information
Masatomo Saneyoshi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.5yrs |
| CEO ownership | 3.0% |
| Management average tenure | 8.5yrs |
| Board average tenure | 6.5yrs |
Recent management updates
CEO
Masatomo Saneyoshi (51 yo)
10.5yrs
Tenure
Mr. Masatomo Saneyoshi has been the President of Techno Medica Co., Ltd., since June 2014 and serves as its Chief Executive Officer since June 01, 2014. Mr. Saneyoshi served as Assistant to The President a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 10.5yrs | no data | 2.99% ¥ 380.1m | |
| GM of Sales Headquarters & Director | 8.3yrs | no data | 0.23% ¥ 29.6m | |
| GM of Medical Solutions Development Department | 8.7yrs | no data | 0.13% ¥ 16.3m | |
| Head of Business Management Division & Director | less than a year | no data | 0.012% ¥ 1.5m |
8.5yrs
Average Tenure
58.5yo
Average Age
Experienced Management: 6678's management team is seasoned and experienced (8.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.5yrs | no data | 2.99% ¥ 380.1m | |
| GM of Sales Headquarters & Director | 15.5yrs | no data | 0.23% ¥ 29.6m | |
| GM of Medical Solutions Development Department | 5.5yrs | no data | 0.13% ¥ 16.3m | |
| Head of Business Management Division & Director | less than a year | no data | 0.012% ¥ 1.5m | |
| Independent Outside Director | 7.5yrs | no data | 0.027% ¥ 3.5m | |
| Independent Outside Director | less than a year | no data | 0.019% ¥ 2.4m |
6.5yrs
Average Tenure
61yo
Average Age
Experienced Board: 6678's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 06:43 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Techno Medica Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Yuta Kenmei | Marusan Securities Co. Ltd. |
| Hidekatsu Watanabe | Mizuho Securities Co., Ltd. |